Xanthic Biopharma Inc. President, Gary Galitsky and Board Member, Dr. Gunther Hintz, Advance Cannabis Opportunity In Thailand
Xanthic Biopharma Inc. (CSE:xTHC) (formerly Aurquest Resources Inc.) (“Xanthic” or the “Company”) is pleased to announce two of its executives, President Gary Galitsky, and Director Dr. Gunther Hintz, made a presentation on April 25, 2018 at a cannabis conference hosted by Bangkok’s Kasetsart University, Thailand’s largest university. The theme of the conference was to educate and teach the benefits of cannabinoid-based medicine, the history of herbal use and the future state of cannabis in the world.
Attendees included the Thai Minister of Health, Director of Drug Enforcement, Justice Minister, Minister of Agriculture, Pharmacological Head of Thailand and over 200 invited attendees, comprised of Thai doctors, pharmacists and medical practitioners. Xanthic was invited to participate in this event by Dr Samnouk, of iMed Therapy Co., Ltd., one of the leading biotechnology companies in Thailand, acting as a key consultant to the Thai government. Thailand has a population of 69 million and is the second largest economy in South East Asia.
Mr. Galitsky and Dr. Hintz presented an overview of Canadian cannabis legal history and the current Canadian legal landscape. Thailand is currently evaluating the decriminalization of cannabis and is looking at Canada as a “best-in-class” source for lessons and best practices.
In addition, Mr. Galitsky and Dr. Hintz introduced the audience to the Xanthic Biopharma patent-pending technology and the benefits of the Xanthic water-soluble THC and CBD product line.
Said Mr. Galitsky: “We are honoured to have been invited to speak at this conference. It is a great opportunity to have some involvement in the evolution of legal change in Thailand and to showcase the benefits of the Xanthic water soluble products. Although it is early days, we look forward to a time when we could create partnerships in Asia to expand the Xanthic footprint.”
Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis, and cannabis-infused products which deliver consistent THC and/or CBD levels. Using a proprietary patent-pending process, Xanthic allows its strategic partners to deliver superior cannabinoid solubility, accurate micro-dosing, faster onset, increased bioavailability and improved consistency versus competitive infused products.
Through its investment in Avitas CBD Water, Xanthic has access to non-cannabis derived CBD infused products that qualify for distribution outside of the Cannabis dispensary network and into mainstream retail.